With the publication of improved survival results of previously untreated patients with acute myeloid leukaemia ineligible for intensive chemotherapy treated with the combination of venetoclax and a hypomethylating agent, the treatment paradigm for patients with AML has been changed. This paper discusses the past, present and future of AML therapy with venetoclax.

(BELG J HEMATOL 2022;13(3):124–7)